Decision-IQ: Integrating Novel Therapies Into Clinical Decision Making in Tardive Dyskinesia
Approximately how many patients taking dopamine receptor–blocking agents such as first- and second-generation antipsychotics eventually develop tardive dyskinesia?
C. 20% to 50%
Approximately 20% to 50% of patients taking dopamine receptor–blocking agents eventually develop tardive dyskinesia, which currently amounts to more than 500,000 people in the United States.1
1. Waln O, Jankovic J. Tremor Other Hyperkinet Mov (NY). 2013;3:tre-03-161-4138-1.
Catherine Campisi, MSN, RN, PMHNP-BC
Psychiatric Mental Health Nurse Practitioner Program
University of Colorado College of Nursing
Amy Burdette, PhD
Manager, Educational Strategy & Content
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Upon completion, participants should be able to:
- Implement best practices to ensure the accurate and consistent use of the AIMS to evaluate patients for TD
- Develop treatment plans for patients with TD that consider their underlying conditions or comorbidities, as well as the efficacy and potential adverse effects associated with pharmacologic treatments
This activity is intended for psychiatric mental health advanced practice registered nurses, psychiatric mental health nurses, and other nurses who prescribe and manage psychiatric medications.
Statement of Need
Approximately 20% to 50% of patients taking long-term antipsychotic therapies eventually develop tardive dyskinesia (TD), which currently amounts to more than 500,000 people in the United States (US). The involuntary and repetitive movements characteristic of TD are embarrassing and debilitating for patients. Moreover, these symptoms often become permanent despite discontinuing or reducing treatment with the causative antipsychotic agent. Previously, TD treatment was limited to off-label options with moderate or weak supporting evidence. Fortunately, in 2017, two novel vesicular monoamine transporter-2 (VMAT2) inhibitors were approved by the US Food and Drug Administration for the treatment of TD, providing effective and tolerable options for patients with this condition. With the introduction of these new therapies, however, clinical practice gaps have become evident, such as the underuse of the Abnormal Involuntary Movement Scale (AIMS) to evaluate patients with suspected TD, treatment practices associated with a decreased likelihood of TD symptom remission, undertreatment of patients’ psychiatric conditions, underuse of VMAT2 inhibitors, and limited consensus on the management of their associated adverse effects.
Provided by Med-IQ.
Med-IQ is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This nursing activity has been approved for up to 0.5 contact hour.
Physicians, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This CE activity consists of a 0.5-credit online publication. To receive credit, read the introductory CE material, read the online publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: August 31, 2018
Expiration Date: August 30, 2019
Estimated Time to Complete This Activity: 30 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Catherine Campisi, MSN, RN, PMHNP-BC, has indicated no real or apparent conflicts.
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email email@example.com.
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Neurocrine Biosciences, Inc.
© 2018 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.